Climate-Sensitive Disease Diagnostics
APAC · 1 shared keyword
APAC Rapid Antigen Tests Market Industry Trends and Forecast to 2034: Segmented by (Disease, User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
APAC · 2024–2034 · estimates
Market Dashboard
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Estimate 2024
$2.17 Bn
Estimated value
Estimate 2025
$2.27 Bn
23.8% of the global market
Projected 2034
$3.41 Bn 49.9%
Adds $1.13 Bn over 9 forecast years
CAGR 2025–2034
4.6%
Faster than 0% of 173 Medical Devices markets here
Key players
5
- APAC is 23.79% of the global market.
- Among regions, the largest is North America at $4.46 Bn.
- Fastest growing: Africa at 4.8% a year.
- APAC ranks 2nd of 6 by size among regions.
Market size projection
APACSource: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
Value added each year
$1.13 Bn total, 2026–2034
Year-by-year market size, 2024–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $2.17 Bn | — | — |
| 2025 (base) | $2.27 Bn | +$99.9 Mn | — |
| 2026 (forecast) | $2.38 Bn | +$104.5 Mn | +4.6% |
| 2027 (forecast) | $2.49 Bn | +$109.3 Mn | +9.4% |
| 2028 (forecast) | $2.60 Bn | +$114.3 Mn | +14.4% |
| 2029 (forecast) | $2.72 Bn | +$119.6 Mn | +19.7% |
| 2030 (forecast) | $2.84 Bn | +$125.1 Mn | +25.2% |
| 2031 (forecast) | $2.98 Bn | +$130.9 Mn | +31% |
| 2032 (forecast) | $3.11 Bn | +$136.9 Mn | +37% |
| 2033 (forecast) | $3.26 Bn | +$143.2 Mn | +43.3% |
| 2034 (forecast) | $3.41 Bn | +$149.8 Mn | +49.9% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
Same market worldwide
By geography
- Global $9.55 Bn
- North America $4.46 Bn
-
US
$4.37 Bn
- APAC (this report) $2.27 Bn
- Europe $1.73 Bn
-
Canada
$844.0 Mn
-
China
$845.1 Mn
-
Japan
$553.9 Mn
- Latin America $466.4 Mn
- Middle East $336.7 Mn
-
Germany
$297.9 Mn
-
France
$289.0 Mn
-
UK
$272.4 Mn
-
Italy
$242.9 Mn
-
Brazil
$246.7 Mn
-
Ecuador
$214.0 Mn
-
Spain
$173.8 Mn
-
India
$183.4 Mn
-
Saudi Arabia
$168.2 Mn
-
Mexico
$153.2 Mn
- Africa $142.8 Mn
-
Australia
$126.0 Mn
-
New Zealand
$99.5 Mn
-
Russia
$99.2 Mn
-
South Africa
$66.4 Mn
-
UAE
$49.1 Mn
-
Egypt
$30.3 Mn
-
Philippines
$18.2 Mn
-
Malaysia
$14.6 Mn
-
Hong Kong
$14.1 Mn
-
Singapore
$12.7 Mn
-
Thailand
$10.3 Mn
-
Kenya
$5.9 Mn
The APAC Rapid Antigen Tests Market Analysis Executive Summary
Rapid antigen tests detect proteins from viruses or bacteria in minutes, used for flu, COVID-19, strep throat and more.
Key segments of the rapid Antigen Tests market include disease (Influenza, COVID-19 and Strep A) and user (Professional and Self-Test).
APAC Rapid Antigen Tests Market Dynamics
Market Growth Drivers
Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the rapid Antigen Tests market.
Opportunity
Home testing, connected devices that send results to doctors and multiplex tests that check many conditions at once give the rapid Antigen Tests market room to grow, especially in emerging markets.
Market Restraints
Pricing pressure, uneven reimbursement for new tests, regulatory approval times and the need for skilled lab staff hold back the rapid Antigen Tests market.
Competitive Landscape for Rapid Antigen Tests Market in APAC
The rapid Antigen Tests market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Key Players
Healthcare Policies and Regulatory Landscape for Rapid Antigen Tests Market in APAC
Policy changes and Reimbursement scenario
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how rapid Antigen Tests products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in APAC.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Rapid Antigen Tests right now, from free public sources.
Latest research 571 papers since 2021 (worldwide)
- Diagnostic performance of antigen-based rapid test kits for six respiratory viruses in children: comparison with a multiplex PCR panel and correlation with viral load. Journal of clinical microbiology, 2026
- Frequency and etiological agents of acute gastroenteritis in children: a retrospective analysis before and during the COVID-19 pandemic. BMC infectious diseases, 2026
- A Kawasaki Disease-Like Presentation in a Child with Concurrent Detection of Group A Streptococcus and Adenovirus: A Case Report on the Characterization of Physical Findings and Short-Interval Reassessment. Reports (MDPI), 2026
- Diagnostic yield of reflex multiplex PCR after a negative rapid antigen test in children hospitalized with presumed viral acute respiratory tract infection: a prospective cohort study. Irish journal of medical science, 2026
- Viral Respiratory Infections: COVID-19. FP essentials, 2026
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
Rapid Antigen Tests in context
Questions, answered with public data
- How much research is published on Rapid Antigen Tests?
- PubMed lists 571 papers added since January 2021 that match this market, worldwide.[1]
[1] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Free data on this topic
- Clinical trials: Diagnostics and lab testing
- New research: Diagnostics and lab testing
- FDA approvals and recalls: Diagnostics and lab testing
- NIH research grants: Diagnostics and lab testing
- Clinical trials: Infectious diseases
- New research: Infectious diseases
- FDA approvals and recalls: Infectious diseases
- NIH research grants: Infectious diseases
From our blog
Dermatology Diagnostics: AI and Skin HealthSkin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…
Molecular Point-of-Care Tests: Lab Accuracy, Clinic SpeedTB killed 1.23 million people in 2024. WHO now recommends rapid molecular tests first, bringing lab-grade…
Healthcare In-Vitro Diagnostics: What Comes After COVIDCOVID-19 testing created a huge, short-lived spike. Long-term demand for in-vitro diagnostics now comes from…